The Danish firm blamed the move to slash its guidance on intense competition from rivals and copycat drugs in the US.

While Novo Nordisk blamed rival drugs and its own tepid expansion for downgrades to sales and profit growth, some analysts ...

While Ozempic is effective at treating type 2 diabetes and supporting weight loss, it can also come with side effects.

Novo Nordisk has lowered its full-year 2025 sales and operating profit forecasts due to weaker-than-expected growth in its ...

The company has looked internally for its new leader, as Doustdar is currently serving as its head of international ...

Novo Nordisk (NVO) is on pace to gap lower at the opening bell today, with shares of the pharma giant plunging up to 30% in ...

Novo Nordisk falls as company slashes 2025 forecasts as US sales of Wegovy and Ozempic face headwinds from compounded drugs.

Danish drugmaker Novo Nordisk, known for its blockbuster diabetes and weight-loss treatments Ozempic and Wegovy, on Tuesday lowered its full-year earnings forecasts again as it unveiled a new chief ...

U.S.-listed shares of Novo Nordisk sank in premarket trading Tuesday after the Danish drugmaker cut its full-year outlook and ...

Investing.com -- Novo Nordisk (NYSE: NVO )’s guidance reduction and CEO resignation represent a "double surprise" according to BMO Capital Markets analyst Evan David Seigerman. In a note to clients, ...

Shares in Novo Nordisk plunged by as much as 30% after the Danish drugmaker cut its guidance and named a new chief executive, pinning its hopes on a company veteran to revive growth.